StreetInsider.com News Articles

Form 10-Q Evolus, Inc. For: Jun 30

Wed, 05 Aug 2026 16:57:00 -0400

si-local-file:///var/storage/secattach/20260805/26875547.html

Form 10-Q Evolus, Inc. For: Jun 30

Wed, 05 Aug 2026 16:57:00 -0400

si-local-file:///var/storage/secattach/20260805/26875547.html

Evolus (EOLS) Misses Q2 EPS by 8c; Offers Guidance

Wed, 05 Aug 2026 16:17:24 -0400

Evolus (NASDAQ: EOLS) reported Q2 EPS of ($0.12), $0.08 worse than the analyst estimate of ($0.04). Revenue for the quarter came in at $84.08 million versus the consensus estimate of $81.89 million.

GUIDANCE:

Evolus sees FY2026 revenue of $330-337 million, versus the consensus of $330.5 million.

For earnings history and earnings-related data on Evolus (EOLS) click here.

Evolus (EOLS) Misses Q2 EPS by 8c; Offers Guidance

Wed, 05 Aug 2026 16:17:24 -0400

Evolus (NASDAQ: EOLS) reported Q2 EPS of ($0.12), $0.08 worse than the analyst estimate of ($0.04). Revenue for the quarter came in at $84.08 million versus the consensus estimate of $81.89 million.

GUIDANCE:

Evolus sees FY2026 revenue of $330-337 million, versus the consensus of $330.5 million.

For earnings history and earnings-related data on Evolus (EOLS) click here.

Form 8-K Evolus, Inc. For: Aug 05

Wed, 05 Aug 2026 16:17:00 -0400

si-local-file:///var/storage/secattach/20260805/26874650.html

Form 8-K Evolus, Inc. For: Aug 05

Wed, 05 Aug 2026 16:17:00 -0400

si-local-file:///var/storage/secattach/20260805/26874650.html

Evolus Reports Strong Second Quarter 2026 Financial Results; Delivers Third Consecutive Quarter of Positive Adjusted EBITDA and Raises Full-Year 2026 Financial Outlook

Wed, 05 Aug 2026 16:05:00 -0400

Global Net Revenue of $84.1 Million for the Second Quarter of 2026, an Increase of 21% Over the Prior Year, Reflecting Increasing Market Share Gains Across U.S. and International Markets
GAAP Operating Loss of $4.5 Million and Positive Adjusted EBITDA of $4.7 Million for the Second Quarter of 2026, Representing the Third Consecutive Quarter of Positive Adjusted EBITDA, a $12.6 Million Year-Over-Year Improvement
Raises Full-Year 2026 Net Revenue Guidance to Between $330 Million and $337 Million, Raises Adjusted Gross Profit Margin Guidance to Between 67.0% and 67.5%, Narrows Non-GAAP Operating Expense Guidance to Between $212 Million and $216 Million, While Reaffirming

Evolus Reports Strong Second Quarter 2026 Financial Results; Delivers Third Consecutive Quarter of Positive Adjusted EBITDA and Raises Full-Year 2026 Financial Outlook

Wed, 05 Aug 2026 16:05:00 -0400

Global Net Revenue of $84.1 Million for the Second Quarter of 2026, an Increase of 21% Over the Prior Year, Reflecting Increasing Market Share Gains Across U.S. and International Markets

GAAP Operating Loss of $4.5 Million and Positive Adjusted EBITDA of $4.7 Million for the Second Quarter of 2026, Representing the Third Consecutive Quarter of Positive Adjusted EBITDA, a $12.6 Million Year-Over-Year Improvement

Raises Full-Year 2026 Net Revenue Guidance to Between $330 Million and $337 Million, Raises Adjusted Gross Profit Margin Guidance to Between 67.0% and 67.5%, Narrows Non-GAAP Operating Expense Guidance to Between $212 Million and $216 Million, While Reaffirming

Evolus Reports Strong Second Quarter 2026 Financial Results; Delivers Third Consecutive Quarter of Positive Adjusted EBITDA and Raises Full-Year 2026 Financial Outlook

Wed, 05 Aug 2026 16:05:00 -0400

Global Net Revenue of $84.1 Million for the Second Quarter of 2026, an Increase of 21% Over the Prior Year, Reflecting Increasing Market Share Gains Across U.S. and International Markets

GAAP Operating Loss of $4.5 Million and Positive Adjusted EBITDA of $4.7 Million for the Second Quarter of 2026, Representing the Third Consecutive Quarter of Positive Adjusted EBITDA, a $12.6 Million Year-Over-Year Improvement

Raises Full-Year 2026 Net Revenue Guidance to Between $330 Million and $337 Million, Raises Adjusted Gross Profit Margin Guidance to Between 67.0% and 67.5%, Narrows Non-GAAP Operating Expense Guidance to Between $212 Million and $216 Million, While Reaffirming

Evolus Reports Strong Second Quarter 2026 Financial Results; Delivers Third Consecutive Quarter of Positive Adjusted EBITDA and Raises Full-Year 2026 Financial Outlook

Wed, 05 Aug 2026 16:05:00 -0400

Global Net Revenue of $84.1 Million for the Second Quarter of 2026, an Increase of 21% Over the Prior Year, Reflecting Increasing Market Share Gains Across U.S. and International Markets

GAAP Operating Loss of $4.5 Million and Positive Adjusted EBITDA of $4.7 Million for the Second Quarter of 2026, Representing the Third Consecutive Quarter of Positive Adjusted EBITDA, a $12.6 Million Year-Over-Year Improvement

Raises Full-Year 2026 Net Revenue Guidance to Between $330 Million and $337 Million, Raises Adjusted Gross Profit Margin Guidance to Between 67.0% and 67.5%, Narrows Non-GAAP Operating Expense Guidance to Between $212 Million and $216 Million, While Reaffirming

Evolus Reports Strong Second Quarter 2026 Financial Results; Delivers Third Consecutive Quarter of Positive Adjusted EBITDA and Raises Full-Year 2026 Financial Outlook

Wed, 05 Aug 2026 16:05:00 -0400

Global Net Revenue of $84.1 Million for the Second Quarter of 2026, an Increase of 21% Over the Prior Year, Reflecting Increasing Market Share Gains Across U.S. and International Markets

GAAP Operating Loss of $4.5 Million and Positive Adjusted EBITDA of $4.7 Million for the Second Quarter of 2026, Representing the Third Consecutive Quarter of Positive Adjusted EBITDA, a $12.6 Million Year-Over-Year Improvement

Raises Full-Year 2026 Net Revenue Guidance to Between $330 Million and $337 Million, Raises Adjusted Gross Profit Margin Guidance to Between 67.0% and 67.5%, Narrows Non-GAAP Operating Expense Guidance to Between $212 Million and $216 Million, While Reaffirming

Evolus Reports Strong Second Quarter 2026 Financial Results; Delivers Third Consecutive Quarter of Positive Adjusted EBITDA and Raises Full-Year 2026 Financial Outlook

Wed, 05 Aug 2026 16:05:00 -0400

Global Net Revenue of $84.1 Million for the Second Quarter of 2026, an Increase of 21% Over the Prior Year, Reflecting Increasing Market Share Gains Across U.S. and International Markets

GAAP Operating Loss of $4.5 Million and Positive Adjusted EBITDA of $4.7 Million for the Second Quarter of 2026, Representing the Third Consecutive Quarter of Positive Adjusted EBITDA, a $12.6 Million Year-Over-Year Improvement

Raises Full-Year 2026 Net Revenue Guidance to Between $330 Million and $337 Million, Raises Adjusted Gross Profit Margin Guidance to Between 67.0% and 67.5%, Narrows Non-GAAP Operating Expense Guidance to Between $212 Million and $216 Million, While Reaffirming

Evolus Reports Strong Second Quarter 2026 Financial Results; Delivers Third Consecutive Quarter of Positive Adjusted EBITDA and Raises Full-Year 2026 Financial Outlook

Wed, 05 Aug 2026 16:05:00 -0400

Global Net Revenue of $84.1 Million for the Second Quarter of 2026, an Increase of 21% Over the Prior Year, Reflecting Increasing Market Share Gains Across U.S. and International Markets

GAAP Operating Loss of $4.5 Million and Positive Adjusted EBITDA of $4.7 Million for the Second Quarter of 2026, Representing the Third Consecutive Quarter of Positive Adjusted EBITDA, a $12.6 Million Year-Over-Year Improvement

Raises Full-Year 2026 Net Revenue Guidance to Between $330 Million and $337 Million, Raises Adjusted Gross Profit Margin Guidance to Between 67.0% and 67.5%, Narrows Non-GAAP Operating Expense Guidance to Between $212 Million and $216 Million, While Reaffirming

Evolus Reports Strong Second Quarter 2026 Financial Results; Delivers Third Consecutive Quarter of Positive Adjusted EBITDA and Raises Full-Year 2026 Financial Outlook

Wed, 05 Aug 2026 16:05:00 -0400

Global Net Revenue of $84.1 Million for the Second Quarter of 2026, an Increase of 21% Over the Prior Year, Reflecting Increasing Market Share Gains Across U.S. and International Markets

GAAP Operating Loss of $4.5 Million and Positive Adjusted EBITDA of $4.7 Million for the Second Quarter of 2026, Representing the Third Consecutive Quarter of Positive Adjusted EBITDA, a $12.6 Million Year-Over-Year Improvement

Raises Full-Year 2026 Net Revenue Guidance to Between $330 Million and $337 Million, Raises Adjusted Gross Profit Margin Guidance to Between 67.0% and 67.5%, Narrows Non-GAAP Operating Expense Guidance to Between $212 Million and $216 Million, While Reaffirming

Evolus Reports Strong Second Quarter 2026 Financial Results; Delivers Third Consecutive Quarter of Positive Adjusted EBITDA and Raises Full-Year 2026 Financial Outlook

Wed, 05 Aug 2026 16:05:00 -0400

Global Net Revenue of $84.1 Million for the Second Quarter of 2026, an Increase of 21% Over the Prior Year, Reflecting Increasing Market Share Gains Across U.S. and International Markets

GAAP Operating Loss of $4.5 Million and Positive Adjusted EBITDA of $4.7 Million for the Second Quarter of 2026, Representing the Third Consecutive Quarter of Positive Adjusted EBITDA, a $12.6 Million Year-Over-Year Improvement

Raises Full-Year 2026 Net Revenue Guidance to Between $330 Million and $337 Million, Raises Adjusted Gross Profit Margin Guidance to Between 67.0% and 67.5%, Narrows Non-GAAP Operating Expense Guidance to Between $212 Million and $216 Million, While Reaffirming

Evolus Reports Strong Second Quarter 2026 Financial Results; Delivers Third Consecutive Quarter of Positive Adjusted EBITDA and Raises Full-Year 2026 Financial Outlook

Wed, 05 Aug 2026 16:05:00 -0400

Global Net Revenue of $84.1 Million for the Second Quarter of 2026, an Increase of 21% Over the Prior Year, Reflecting Increasing Market Share Gains Across U.S. and International Markets

GAAP Operating Loss of $4.5 Million and Positive Adjusted EBITDA of $4.7 Million for the Second Quarter of 2026, Representing the Third Consecutive Quarter of Positive Adjusted EBITDA, a $12.6 Million Year-Over-Year Improvement

Raises Full-Year 2026 Net Revenue Guidance to Between $330 Million and $337 Million, Raises Adjusted Gross Profit Margin Guidance to Between 67.0% and 67.5%, Narrows Non-GAAP Operating Expense Guidance to Between $212 Million and $216 Million, While Reaffirming

Evolus Reports Strong Second Quarter 2026 Financial Results; Delivers Third Consecutive Quarter of Positive Adjusted EBITDA and Raises Full-Year 2026 Financial Outlook

Wed, 05 Aug 2026 16:05:00 -0400

Global Net Revenue of $84.1 Million for the Second Quarter of 2026, an Increase of 21% Over the Prior Year, Reflecting Increasing Market Share Gains Across U.S. and International Markets

GAAP Operating Loss of $4.5 Million and Positive Adjusted EBITDA of $4.7 Million for the Second Quarter of 2026, Representing the Third Consecutive Quarter of Positive Adjusted EBITDA, a $12.6 Million Year-Over-Year Improvement

Raises Full-Year 2026 Net Revenue Guidance to Between $330 Million and $337 Million, Raises Adjusted Gross Profit Margin Guidance to Between 67.0% and 67.5%, Narrows Non-GAAP Operating Expense Guidance to Between $212 Million and $216 Million, While Reaffirming

Evolus Reports Strong Second Quarter 2026 Financial Results; Delivers Third Consecutive Quarter of Positive Adjusted EBITDA and Raises Full-Year 2026 Financial Outlook

Wed, 05 Aug 2026 16:05:00 -0400

Global Net Revenue of $84.1 Million for the Second Quarter of 2026, an Increase of 21% Over the Prior Year, Reflecting Increasing Market Share Gains Across U.S. and International Markets

GAAP Operating Loss of $4.5 Million and Positive Adjusted EBITDA of $4.7 Million for the Second Quarter of 2026, Representing the Third Consecutive Quarter of Positive Adjusted EBITDA, a $12.6 Million Year-Over-Year Improvement

Raises Full-Year 2026 Net Revenue Guidance to Between $330 Million and $337 Million, Raises Adjusted Gross Profit Margin Guidance to Between 67.0% and 67.5%, Narrows Non-GAAP Operating Expense Guidance to Between $212 Million and $216 Million, While Reaffirming

Evolus Reports Strong Second Quarter 2026 Financial Results; Delivers Third Consecutive Quarter of Positive Adjusted EBITDA and Raises Full-Year 2026 Financial Outlook

Wed, 05 Aug 2026 16:05:00 -0400

Global Net Revenue of $84.1 Million for the Second Quarter of 2026, an Increase of 21% Over the Prior Year, Reflecting Increasing Market Share Gains Across U.S. and International Markets

GAAP Operating Loss of $4.5 Million and Positive Adjusted EBITDA of $4.7 Million for the Second Quarter of 2026, Representing the Third Consecutive Quarter of Positive Adjusted EBITDA, a $12.6 Million Year-Over-Year Improvement

Raises Full-Year 2026 Net Revenue Guidance to Between $330 Million and $337 Million, Raises Adjusted Gross Profit Margin Guidance to Between 67.0% and 67.5%, Narrows Non-GAAP Operating Expense Guidance to Between $212 Million and $216 Million, While Reaffirming

Evolus Reports Strong Second Quarter 2026 Financial Results; Delivers Third Consecutive Quarter of Positive Adjusted EBITDA and Raises Full-Year 2026 Financial Outlook

Wed, 05 Aug 2026 16:05:00 -0400

Global Net Revenue of $84.1 Million for the Second Quarter of 2026, an Increase of 21% Over the Prior Year, Reflecting Increasing Market Share Gains Across U.S. and International Markets

GAAP Operating Loss of $4.5 Million and Positive Adjusted EBITDA of $4.7 Million for the Second Quarter of 2026, Representing the Third Consecutive Quarter of Positive Adjusted EBITDA, a $12.6 Million Year-Over-Year Improvement

Raises Full-Year 2026 Net Revenue Guidance to Between $330 Million and $337 Million, Raises Adjusted Gross Profit Margin Guidance to Between 67.0% and 67.5%, Narrows Non-GAAP Operating Expense Guidance to Between $212 Million and $216 Million, While Reaffirming

Evolus Reports Strong Second Quarter 2026 Financial Results; Delivers Third Consecutive Quarter of Positive Adjusted EBITDA and Raises Full-Year 2026 Financial Outlook

Wed, 05 Aug 2026 16:05:00 -0400

Global Net Revenue of $84.1 Million for the Second Quarter of 2026, an Increase of 21% Over the Prior Year, Reflecting Increasing Market Share Gains Across U.S. and International Markets

GAAP Operating Loss of $4.5 Million and Positive Adjusted EBITDA of $4.7 Million for the Second Quarter of 2026, Representing the Third Consecutive Quarter of Positive Adjusted EBITDA, a $12.6 Million Year-Over-Year Improvement

Raises Full-Year 2026 Net Revenue Guidance to Between $330 Million and $337 Million, Raises Adjusted Gross Profit Margin Guidance to Between 67.0% and 67.5%, Narrows Non-GAAP Operating Expense Guidance to Between $212 Million and $216 Million, While Reaffirming

Evolus Reports Strong Second Quarter 2026 Financial Results; Delivers Third Consecutive Quarter of Positive Adjusted EBITDA and Raises Full-Year 2026 Financial Outlook

Wed, 05 Aug 2026 16:05:00 -0400

Global Net Revenue of $84.1 Million for the Second Quarter of 2026, an Increase of 21% Over the Prior Year, Reflecting Increasing Market Share Gains Across U.S. and International Markets

GAAP Operating Loss of $4.5 Million and Positive Adjusted EBITDA of $4.7 Million for the Second Quarter of 2026, Representing the Third Consecutive Quarter of Positive Adjusted EBITDA, a $12.6 Million Year-Over-Year Improvement

Raises Full-Year 2026 Net Revenue Guidance to Between $330 Million and $337 Million, Raises Adjusted Gross Profit Margin Guidance to Between 67.0% and 67.5%, Narrows Non-GAAP Operating Expense Guidance to Between $212 Million and $216 Million, While Reaffirming

Form 8-K Evolus, Inc. For: Aug 03

Tue, 04 Aug 2026 08:46:00 -0400
si-local-file:///var/storage/secattach/20260804/26862552.html

Form 8-K Evolus, Inc. For: Aug 03

Tue, 04 Aug 2026 08:46:00 -0400
si-local-file:///var/storage/secattach/20260804/26862552.html

Evolus expands Symatese deal to sell Estyme in Canada and Oceania

Tue, 04 Aug 2026 08:30:19 -0400

Evolus, Inc. (NASDAQ: EOLS) has amended its existing licensing and distribution agreement with Symatese to gain exclusive rights to commercialize the Estyme® collection of injectable hyaluronic acid (HA) gels in Canada, Australia, and New Zealand, according to a press release from the company.

Commercialization is expected in 2028, subject to regulatory approvals. The Estyme® collection is currently marketed in the United States under the brand name Evolysse®. The expansion means Evolus will hold exclusive rights to its injectable HA gel portfolio in every market where it currently sells its neurotoxin products Jeuveau® and Nuceiva®.

The combined neurotoxin and dermal filler markets across